DOCOMO and YKK AP to Test Signal-permeable Windows Made with Aerogel for Easy Penetration by Radio Waves JCN Newswire

DOCOMO and YKK AP to Test Signal-permeable Windows Made with Aerogel for Easy Penetration by Radio Waves

January 30, 2023
TOKYO, Jan 30, 2023 - (JCN Newswire via SEAPRWire.com) - NTT DOCOMO, INC. announced today that in collaboration with YKK AP Inc. it has launched a demonstration test to verify the radio-wave penetration characteristics of signal-permeable windows made with a light, porous material called aerogel, aiming to improve indoor reception of external radio waves while maintaining the insulation benefits of windows.High-performance materials, multilayered window glass and Low-E glass are being used more widely to improve the insulation of homes and offices for energy efficiency. As a consequence, however, it is becoming more difficult for high-frequency radio waves used by cellphones and other applications to reach indoor spaces. In response, DOCOMO and YKK AP are developing windows that allow radio waves to pass through easily while still maintaining high-performance thermal insulation. The plan is eventually to install such windows in the ceilings and walls of existing as well as new homes and offices.DOCOMO and YKK AP will now test a prototype window made with aerogel, a high-performance thermal-insulation gel-like material, to confirm its radio-wave penetration characteristics. Aerogel is known to have a dielectric constant close to that of air and allows radio waves to penetrate easily. The demonstration will enable DOCOMO to test materials, shapes and window structures that best allow radio waves to pass through.Going forward, DOCOMO will continue to work toward 5G Evolution & 6G by researching and developing technologies including windows easily penetrated by high-frequency millimeter and terahertz radio waves for high-quality indoor connectivity.The initiative will be introduced during "docomo Open House '23," which will be held online from Thursday, February 2 through the rest of the month. Please visit:www.docomo.ne.jp/english/corporate/technology/rd/openhouse/openhouse2023/About NTT DOCOMONTT DOCOMO, Japan's leading mobile operator with over 85 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations. www.docomo.ne.jp/english/. Copyright 2023 JCN Newswire. All rights reserved. (via SEAPRWire)
More

Alercell Is All Set to Launch a Leukemia Diagnostic Test Lena Q51(R)

December 29, 2022
Bozeman, MT, December 29, 2022 – (SEAPRWire) – Alercell is all set to launch LENA Q51(R) in January 2023. A leukemia diagnostic test based on sequencing DNA will detect up to 51 Genes mutations in Leukemia patients. Alercell is on a mission of making a significant difference in the fight against cancer by offering unique and precise diagnostic solutions that enhance patient outcomes. Alercell is a young and dynamic firm. To better fulfill the demands of the clients, they are continually working to improve their products and services. They have an active research and development program to create new goods for even more precise testing, and their products are based on the most recent technology. Alercell, Inc. seeks to provide innovative in-vitro testability for cancer testing while streamlining the process of detecting infectious diseases. In their ideal world, early disease detection is achieved by testing, allowing prompt implementation of preventative measures. Alercell is based in the United States, but they also have manufacturing and storage facilities in Europe and Asia, extending its accessibility and reach around the globe. In July 2020, the first Alercell COVID-19 fast test arrived in the USA. Since then, Alercell has created a stir in the sector by creating new, creative methods for conducting tests that are more precise, effective, and easily accessible. Being a molecular diagnostics startup, Alercell, Inc. also offers quick testing for leukemia and cancer to detect life-threatening conditions as soon as possible. The company was established to give cancer patients worldwide better precise and rapid diagnostic tools. By offering unique and accurate diagnostic solutions that enhance patient outcomes, Alercell aims to contribute to the fight against cancer. “Stopping it before it starts” is the cornerstone of the Alercell mission. Our genetic testing is the first defense against cancer, leukemia, and infectious diseases. Bozeman, Montana-based Alercell is a biotechnology business with a R&D branch in New York City. Alercell will soon introduce a new test and brand. The first leukemia diagnostic test, LENA Q51®, was based on DNA sequencing and could identify up to 51 gene alterations in leukemia patients. An intriguing development is this test. Until recently, a series of blood tests and a bone marrow biopsy were required when someone was “suspected” to have leukemia. It costs thousands of dollars and takes somewhere between 6 and 9 weeks. With LENA Q51®, all of this is avoided, and in just three hours using a qPCR machine, clinicians will be able to identify any gene mutations among 51 different genes. By doing this, we can determine in 3 hours via computer, eliminating the need for human interpretation; the information gathered will also enable us to tailor the patient’s treatment—all of this for a much lower price. Moreover, the fight against the most lethal cancer, lung cancer in the US is a first. The first methylation-based molecular diagnostic test for lung cancer, LENA S1®, will be made available by Alercell later in the first quarter of 2023. As an epigenetic regulator of gene expression, DNA methylation enables early diagnosis of lung cancer and very accurate localization of the disease, if present. Alercell Neuroscience will make a formal announcement in early 2023. Alercell Neuroscience aims to create a nanoparticle neural interface for recording and controlling brain activity. Prof. Gleb Sukhorukov, Ph.D., Chair in Biopolymers at the School of Engineering and Materials Science, Queen Mary University of London (QMUL), will spearhead our efforts. Professor Sukhorukov is a renowned scientist around the globe. Alercell plays a significant role in preventative medicine, particularly in the detection and treatment of cancer. The CEO and the CMO of the company, Dr. Alexandre Scheer MD, are leveraging genetic research to develop novel drugs and testing procedures. Scheer thinks that genetic science holds the answer to improving early diagnosis and eventually identifying severe illnesses before they manifest inside the body. By employing such techniques, the healthcare system may save a large sum of money, and patients may receive excellent care before grueling chemotherapy treatments. Scheer is particularly sensitive to this subject since he is undergoing all these challenging therapies while battling severe cancer. Frederic Scheer stated, “I want to let people know well in advance to avoid what I am going through”. Alercell, Inc. co-founder Frederic Scheer successfully floated multiple start-up firms on stock-exchanges including NASDAQ and NYSE. For the past 25 years, he has worked in the chemical business and alternative technology. Scheer holds 15 US biotechnology patents including three on nanoparticles. As the co-founder of Alercell Inc. “I am thrilled that via the application of our knowledge of the genome, we are now able to produce very performing tests that will help people in finally avoiding the unpleasant traditional treatment,” he says regarding the company’s goods. The business focuses on collaborating with reputed pharmaceutical firms and other healthcare organizations to benefit its patients and ensure that the public always has access to the quickest diagnostic procedures and most affordable medications.” Media Contact Brand: ALERCELL, INC. Contact: Frederic Scheer E-Mail: fscheer@alercell.com Website: https://alercell.com SOURCE: ALERCELL The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)
More
MHI Delivers Testing Equipment for Safety Demonstration of Nuclear Fusion Blankets for ITER in Southern France JCN Newswire

MHI Delivers Testing Equipment for Safety Demonstration of Nuclear Fusion Blankets for ITER in Southern France

July 6, 2022
TOKYO, Jul 6, 2022 - (JCN Newswire via SEAPRWire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) has completed delivery of testing equipment to the Rokkasho Fusion Institute in Aomori Prefecture, part of Japan's National Institutes for Quantum Science and Technology (QST), to confirm and demonstrate the safety of the "blanket," a core component of a nuclear fusion reactor. The blanket system being developed at this research center will be used as Japan's Test Blanket Module (TBM) for the ITER-TBM project, the world's first test of blanket systems in an actual reactor environment, at ITER(1), the experimental fusion reactor currently under construction in southern France. Following the delivery of testing equipment, MHI has strong intention to contribute to the development of a blanket system for the ITER-TBM project through providing other systems/components such as TBMs.The testing equipment supplied by MHI comprises four systems, the High Heat Flux Test Equipment, In Box Water Eruption Test Equipment, Be-Water Reaction Test Equipment, and Flow Assisted Corrosion Test Loop. These testing systems will be used for various experiments aimed at developing a blanket system for the ITER-TBM project, and to confirm its safety. The blanket is one of the components that comprises the inner wall of the fusion reactor. It is a critical component that extracts the heat generated by the reactor, as well as provides for breeding and self-sustainment(2) of tritium, which is used as fuel.ITER is an international megaproject to demonstrate, both scientifically and technologically, the feasibility of fusion energy. ITER-TBM is a project to conduct functional demonstration testing of different TBM systems, each developed independently by four of the seven participating parties (Japan, the EU, the U.S., Russia, South Korea, China, and India). Because the results from this project will influence the relative merits of blanket systems for commercial reactors in the future, each country is actively developing TBMs with demonstrated functionality and safety. In Japan, QST, as the domestic agency for the ITER Project, is leading the development of the country's blanket system.MHI was previously awarded contracts from QST for manufacture of core components for ITER, including five (of a total of 19) toroidal field (TF) coils(3), four of which have been shipped, and six units of the divertor outer vertical targets(4), which are currently being manufactured. MHI will continue to actively support the ITER project to develop this technology, which will be vital to the stable development of the world, and contribute to the realization of fusion energy.(1) Fusion is the energy source that enables the sun to keep shining. The ultimate goal is achieving fusion on Earth. Fusion reactions fuse light atomic nuclei (deuterium and tritium) in a plasma environment into the heavier element of helium. Fusion reactions emit zero carbon dioxide, and their source of fuel can be extracted from seawater in virtually unlimited quantities (lithium from which tritium is derived, and deuterium). Fusion energy is expected to provide fundamental solutions to many of the world's energy and environmental problems.(2) Fusion reactors use deuterium and tritium as fuel. Neutron irradiation of a lithium compound in the blanket is used to produce and supplement the tritium that is consumed in the reaction process (self-sustainment).(3) For details on the TF coils for ITER that QST ordered from MHI, see the following press release. www.mhi.com/news/210524.html4For details on the divertor outer vertical targets for ITER that QST ordered from MHI, see the following press release. www.mhi.com/news/211213.htmlAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More